医学
体外循环
肌钙蛋白I
心肌保护
围手术期
心脏外科
背景(考古学)
麻醉
心脏病学
缺血
心肌梗塞
古生物学
生物
作者
Pascal Chiari,Olivier Desebbe,M. Durand,Marc-Olivier Fischer,Diane Lena-Quintard,Jean-Charles Palao,Géraldine Samson,Yvonne Varillon,Bernadette VAZ,P.-A. Joseph,Anna Maria Ferraris,Matthias Jacquet-Lagrèze,Mattéo Pozzi,Delphine Maucort‐Boulch,Michel Ovize,Gabriel Bidaux,Nathan Mewton,Jean-Luc Fellahi
标识
DOI:10.1053/j.jvca.2023.04.011
摘要
Objective The ProCCard study tested whether combining several cardioprotective interventions would reduce the myocardial and other biological and clinical damage in patients undergoing cardiac surgery. Design Prospective, randomized, controlled trial. Setting Multicenter tertiary care hospitals. Participants 210 patients scheduled to undergo aortic valve surgery. Interventions A control group (standard of care) was compared to a treated group combining five perioperative cardioprotective techniques: anesthesia with sevoflurane, remote ischemic preconditioning, close intraoperative blood glucose control, moderate respiratory acidosis (pH 7.30) just before aortic unclamping (concept of the “pH paradox”), and gentle reperfusion just after aortic unclamping. Measurements and Main Results The primary outcome was the postoperative 72-h area under the curve (AUC) for high-sensitivity cardiac troponin I (hsTnI). Secondary endpoints were biological markers and clinical events occurring during the 30 postoperative days and the prespecified subgroup analyses. The linear relationship between the 72-h AUC for hsTnI and aortic clamping time, significant in both groups (p < 0.0001), was not modified by the treatment (p = 0.57). The rate of adverse events at 30 days was identical. A non-significant reduction of the 72-h AUC for hsTnI (−24%, p = 0.15) was observed when sevoflurane was administered during cardiopulmonary bypass (46% of patients in the treated group). The incidence of postoperative renal failure was not reduced (p = 0.104). Conclusion This multimodal cardioprotection has not demonstrated any biological or clinical benefit during cardiac surgery. The cardio- and reno-protective effects of sevoflurane and remote ischemic preconditioning therefore remain to be demonstrated in this context. The ProCCard study tested whether combining several cardioprotective interventions would reduce the myocardial and other biological and clinical damage in patients undergoing cardiac surgery. Prospective, randomized, controlled trial. Multicenter tertiary care hospitals. 210 patients scheduled to undergo aortic valve surgery. A control group (standard of care) was compared to a treated group combining five perioperative cardioprotective techniques: anesthesia with sevoflurane, remote ischemic preconditioning, close intraoperative blood glucose control, moderate respiratory acidosis (pH 7.30) just before aortic unclamping (concept of the “pH paradox”), and gentle reperfusion just after aortic unclamping. The primary outcome was the postoperative 72-h area under the curve (AUC) for high-sensitivity cardiac troponin I (hsTnI). Secondary endpoints were biological markers and clinical events occurring during the 30 postoperative days and the prespecified subgroup analyses. The linear relationship between the 72-h AUC for hsTnI and aortic clamping time, significant in both groups (p < 0.0001), was not modified by the treatment (p = 0.57). The rate of adverse events at 30 days was identical. A non-significant reduction of the 72-h AUC for hsTnI (−24%, p = 0.15) was observed when sevoflurane was administered during cardiopulmonary bypass (46% of patients in the treated group). The incidence of postoperative renal failure was not reduced (p = 0.104). This multimodal cardioprotection has not demonstrated any biological or clinical benefit during cardiac surgery. The cardio- and reno-protective effects of sevoflurane and remote ischemic preconditioning therefore remain to be demonstrated in this context.
科研通智能强力驱动
Strongly Powered by AbleSci AI